243 related articles for article (PubMed ID: 17687345)
1. Clinical setbacks for toll-like receptor 9 agonists in cancer.
Schmidt C
Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
[No Abstract] [Full Text] [Related]
2. The second wave in kinase cancer drugs.
Garber K
Nat Biotechnol; 2006 Feb; 24(2):127-30. PubMed ID: 16465146
[No Abstract] [Full Text] [Related]
3. Oncology's trials.
Booth B; Glassman R; Ma P
Nat Rev Drug Discov; 2003 Aug; 2(8):609-10. PubMed ID: 12908467
[No Abstract] [Full Text] [Related]
4. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.
Krieg AM
Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597
[TBL] [Abstract][Full Text] [Related]
5. The development of erythropoietic agents in oncology.
Glaspy JA
Expert Opin Emerg Drugs; 2005 Aug; 10(3):553-67. PubMed ID: 16083329
[TBL] [Abstract][Full Text] [Related]
6. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
7. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
8. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Forster MD; Saijo N; Seymour L; Calvert H
Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
[TBL] [Abstract][Full Text] [Related]
9. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
10. Industry shifts focus to immunology and cancer.
Ledford H
Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
[No Abstract] [Full Text] [Related]
11. Tysabri's troubles return.
Hoag H
Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
[No Abstract] [Full Text] [Related]
12. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
13. Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y
Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
[No Abstract] [Full Text] [Related]
14. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Ratain MJ; Eckhardt SG
J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
[No Abstract] [Full Text] [Related]
15. Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci. Interview by Ingrid Torjesen, BSc.
Sykes R
Circulation; 2006 Jun; 113(22):f85-6. PubMed ID: 16754809
[No Abstract] [Full Text] [Related]
16. Trading on traditional medicines.
Basu P
Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
[No Abstract] [Full Text] [Related]
17. Drug development research: diabetes favored over cardiovascular disease?
Suckling K
Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
[No Abstract] [Full Text] [Related]
18. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
19. Project data sphere to make cancer clinical trial data publicly available.
Hede K
J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505
[No Abstract] [Full Text] [Related]
20. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
Fiorino T
J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
